The aim of this work was to load an anticancer drug, paclitaxel (PTX), on Silk Fibroin Nanoparticles (SFNs) by using an exogenous approach. SFNs were produced, freeze-dried and then loaded with PTX. An exogenous method allowed us to reduce both drug loss and environmental impact. In order to quantify PTX loaded in SFNs, a simple and reliable method using reversed phase liquid chromatography coupled to tandem mass spectrometry (rp-UHPLC-MS/MS) was developed. This methodology was validated by the determination of spiked QC samples in three consecutive days. Good accuracy and precision of the method were obtained, while the intra-day and inter-day precisions were less than 10.3%. For PTX, the limit of quantitation (LOQ) was 5.0 ng/mL. Recovery from the matrix (SFNs-PTX pellets) was calculated (81.2% at LOQ value) as PTX was entrapped in a new matrix like the polymer silk fibroin-based. This method was successfully applied to determine the encapsulation effciency (1.00 ± 0.19%) and the nanoparticle loading (0.12 ± 0.02% w/w). The in vitro anticancer activity of SFNs-PTX was tested against CFPAC-1 cancer cells; results demonstrated a very high cytotoxic activity of SFNs-PTX, with a dose dependent inhibition of CFPAC-1 proliferation, confirmed by the IC50 value of 3450 ± 750 ng/mL.

Paclitaxel-loaded silk fibroin nanoparticles : Method validation by UHPLC-MS/MS to assess an exogenous approach to load cytotoxic drugs / S. Perteghella, C. Sottani, V. Cocce', S. Negri, L. Cavicchini, G. Alessandri, D. Cottica, M.L. Torre, E. Grignani, A. Pessina. - In: PHARMACEUTICS. - ISSN 1999-4923. - 11:6(2019 Jun 17), pp. 285.1-285.15. [10.3390/pharmaceutics11060285]

Paclitaxel-loaded silk fibroin nanoparticles : Method validation by UHPLC-MS/MS to assess an exogenous approach to load cytotoxic drugs

V. Cocce';L. Cavicchini;A. Pessina
2019

Abstract

The aim of this work was to load an anticancer drug, paclitaxel (PTX), on Silk Fibroin Nanoparticles (SFNs) by using an exogenous approach. SFNs were produced, freeze-dried and then loaded with PTX. An exogenous method allowed us to reduce both drug loss and environmental impact. In order to quantify PTX loaded in SFNs, a simple and reliable method using reversed phase liquid chromatography coupled to tandem mass spectrometry (rp-UHPLC-MS/MS) was developed. This methodology was validated by the determination of spiked QC samples in three consecutive days. Good accuracy and precision of the method were obtained, while the intra-day and inter-day precisions were less than 10.3%. For PTX, the limit of quantitation (LOQ) was 5.0 ng/mL. Recovery from the matrix (SFNs-PTX pellets) was calculated (81.2% at LOQ value) as PTX was entrapped in a new matrix like the polymer silk fibroin-based. This method was successfully applied to determine the encapsulation effciency (1.00 ± 0.19%) and the nanoparticle loading (0.12 ± 0.02% w/w). The in vitro anticancer activity of SFNs-PTX was tested against CFPAC-1 cancer cells; results demonstrated a very high cytotoxic activity of SFNs-PTX, with a dose dependent inhibition of CFPAC-1 proliferation, confirmed by the IC50 value of 3450 ± 750 ng/mL.
No
English
Method validation; Nanoparticles; Paclitaxel; Silk fibroin; UHPLC-MS/MS
Settore BIO/13 - Biologia Applicata
Articolo
Esperti anonimi
Pubblicazione scientifica
17-giu-2019
MDPI
11
6
285
1
15
15
Pubblicato
Periodico con rilevanza internazionale
scopus
Aderisco
info:eu-repo/semantics/article
Paclitaxel-loaded silk fibroin nanoparticles : Method validation by UHPLC-MS/MS to assess an exogenous approach to load cytotoxic drugs / S. Perteghella, C. Sottani, V. Cocce', S. Negri, L. Cavicchini, G. Alessandri, D. Cottica, M.L. Torre, E. Grignani, A. Pessina. - In: PHARMACEUTICS. - ISSN 1999-4923. - 11:6(2019 Jun 17), pp. 285.1-285.15. [10.3390/pharmaceutics11060285]
open
Prodotti della ricerca::01 - Articolo su periodico
10
262
Article (author)
no
S. Perteghella, C. Sottani, V. Cocce', S. Negri, L. Cavicchini, G. Alessandri, D. Cottica, M.L. Torre, E. Grignani, A. Pessina
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-11-00285.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 5.27 MB
Formato Adobe PDF
5.27 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/780718
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact